AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00757705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Participants will receive paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day orally once daily for 24 weeks as per Investigator's discretion based on the individual participant's clinical response to and tolerability of the study drug.
Study NCT02028416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG-fresenius
Description: we will create 2 arms as per randomization table. Both arms will receive ATG-Fresenius but with 2 different regimens.~the first arm will receive ATG-F @10mg/kg for 3 days and second arm will receive ATG-F same dose but for 5 days
Study NCT02028416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-fresenius
Description: we will create 2 arms as per randomization table. Both arms will receive ATG-Fresenius but with 2 different regimens.~the first arm will receive ATG-F @10mg/kg for 3 days and second arm will receive ATG-F same dose but for 5 days
Study NCT01567319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Skin Prick Test
Description: Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
Study NCT01567319 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Skin Prick Test - Atopic Subjects
Description: Skin prick test of 4 concentrations of each allergenic source,together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
Study NCT01567319 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Skin Prick Test - No Atopic Subjects
Description: Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
Study NCT03196557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prenisolone
Description: Specified dose on specified days
Study NCT04148677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Protoves M1®
Description: A combination of two alkaloid, Protopine and Nuciferine (Protoves-M1 ®)
Study NCT03598634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: administration of riboflavin for epi-off cross-linking
Description: riboflavin 0.1% in 20% dextran solution
Study NCT03598634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: administration of riboflavin for epi-on cross-linking
Description: riboflavin 0.1% in 15% dextran solution supplemented with tris-hydroxymethylaminomethane and sodium ethylenediminetetraacetic acid
Study NCT01830075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultations
Description: The patients receive two consultations with a spiritual counsellor. In these consultations life evens and life goals are discussed.
Study NCT02337348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Description: Preintervention imaging
Study NCT02337348 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angiography
Description: Conventional coronary intervention
Study NCT02337348 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Coronary angiography
Description: Conventional coronary intervention
Study NCT03117049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Study NCT03117049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Study NCT03117049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Study NCT03117049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Study NCT03117049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Study NCT03172546 — intervention group
Intervention type: GENETIC
Intervention: PK-PD genetic polymorphisms
Description: PK-PD genetic polymorphisms analysis in patients receiving either anti-IIa or anti-Xa treatment
Study NCT04594408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: 1 mL of 1:1000 mixed into irrigation bag.
Study NCT04594408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 1 g IV x 1 dose to be administered intraoperatively.
Study NCT04594408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine and Tranexamic Acid
Description: 1 mL of 1:1000 epinephrine mixed into irrigation bag, and 1 g tranexamic acid x 1 dose to be administered intraoperatively.
Study NCT03880227 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active anodal tDCS
Description: active anodal tDCS with behavioral tasks to assess visual attention
Study NCT03880227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active anodal tDCS
Description: active anodal tDCS with behavioral tasks to assess visual attention
Study NCT03382171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FoodforCare at home
Description: Five small protein rich meals that will be delivered twice a week for 3 weeks.
Study NCT01034475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: This is a Phase I open label trial using a 2-stage dose-escalation scheme (single-patient \& traditional stages):~Single-Patient Dose-Escalation Stage: In the single-patient stage, a single patient will be accrued per dose level. The starting dose will be 420 mg/m². Dose level will be escalated (by doubling the previous dose) if there is no toxicity or if the toxicity is grade 1 or less. If toxicity is >Grade 1, the traditional dose-escalation stage will be triggered.~Traditional Dose-Escalation: All dose escalations conducted in this Traditional Dose-Escalation stage will be escalated according to the modified Fibonacci Dose-Escalation scheme.
Study NCT01219465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cells
Description: Transfusion of the umbilical cord mesenchymal stem cells (2 x 107 cells) intravenously.
Study NCT03196557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on dose on specified days
Study NCT01608906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose intravenous heparin (LDIVH)
Description: The LDIVH (experimental) group will receive a continuous heparin drip titrated to a prothrombin time (PTT) of 40-45. LDIVH subjects will have PTT tested within 24 hours prior to initiation of LDIVH. In addition, these subjects would continue to have a PTT tested every 6 hours until the PTT value falls between 40-45. All LDIVH subjects will have PTT values measured at least daily. This will continue until ICU discharge or a maximum of 28 days.
Study NCT01608906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: 5000 units given subcutaneously three times a day until ICU discharge or a maximum of 28 days
Study NCT03880227 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham tDCS
Description: sham tDCS with behavioral tasks to assess visual attention
Study NCT03880227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: sham tDCS with behavioral tasks to assess visual attention
Study NCT00666614 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sleep Environment Intervention
Description: Patients randomized to the sleep environment intervention months will experience a relaxation period before nighttime sleep, white noise as selected by the patient, stimulus control strategies, a window covering to diminish hallway light from entering the room, and a nurse-protected 90-minute uninterrupted sleep period at night.
Study NCT00666614 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normal Hospital Environment
Description: Normal Hospital Environment
Study NCT00088881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00088881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study NCT00088881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00088881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Given IV
Study NCT00088881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Given IV
Study NCT00088881 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: indium In 111 ibritumomab tiuxetan
Description: Given IV
Study NCT00088881 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT00088881 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo PET scans
Study NCT00688493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 3 x 50 mg tablets, single oral dose
Study NCT00688493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 3 x 50 mg tablets, single oral dose
Study NCT00688493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin
Description: 3 x 50 mg tablets, single oral dose
Study NCT00688493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 2 x 10 mg capsules, single oral dose
Study NCT01949675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell
Description: 1.5 mL, Oral administration
Study NCT04562805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DynamX Bioadaptor
Description: DynamX Bioadaptor Treatment
Study NCT00688493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 2 x 10 mg capsules, single oral dose
Study NCT00688493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin
Description: 2 x 10 mg capsules, single oral dose
Study NCT00688493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Overencapsulated 400 mg capsule, single oral dose
Study NCT00688493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Overencapsulated 400 mg capsule, single oral dose
Study NCT03359681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: metformin 500mg three times a day 20 days before colon cancer surgery and 10 days after.
Study NCT00688493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: Overencapsulated 400 mg capsule, single oral dose
Study NCT00688493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match moxifloxacin and dapagliflozin
Description: Overencapsulated 400 mg capsule, single oral dose
Study NCT03359681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: placebo 500mg three times a day 20 days before colon cancer surgery and 10 days after.
Study NCT04562805 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Onyx
Description: Resolute Onyx Treatment
Study NCT01901549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal denervation
Description: The treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
Study NCT01901549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Beta-blockers. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
Study NCT00688493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match moxifloxacin and dapagliflozin
Description: Overencapsulated 400 mg capsule, single oral dose
Study NCT01901549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: ACE inhibitors. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
Study NCT00688493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match moxifloxacin and dapagliflozin
Description: Overencapsulated 400 mg capsule, single oral dose
Study NCT03344159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated for a total duration of 12 weeks.
Study NCT03344159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for a total of duration of 12 weeks
Study NCT03761914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: galinpepimut-S
Description: * Induction phase: the first two GPS + Montanide injections are administered Q3W on Week 0 and Week 3. Thereafter, GPS + Montanide is co-administered with pembrolizumab Q3W (Weeks 6, 9, 12, 15, 18).~* Early immune booster phase: A single administration of pembrolizumab (Week 21), and then GPS + Montanide resumes Q3W for six additional doses (Weeks 24, 27, 30, 33, 36, 39).~* Following the early immune booster, there is a 12-week interval of pembrolizumab administration (Weeks 42, 45, 48, 51), and then GPS is resumed every 12 weeks for an additional four doses.~* After 84 weeks, participants who had not progressed will continue in the study and be treated with pembrolizumab alone.
Study NCT02082834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abdominal MDCT examination
Study NCT02928627 — intervention group
Intervention type: OTHER
Intervention: Analysis of microRNA expression
Description: sample analysis
Study NCT01597349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP01
Description: Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.
Study NCT03952065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1/PDL1/CTLA4 inhibitors
Description: Infusion of PD1/PDL1/CTLA4 inhibitors through peripheral vein or neck artery/intra-tumor.
Study NCT03344159 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82
Description: At baseline and 12 weeks, all participants will undergo rest perfusion PET imaging according to standard protocols with either 82-Rb or N-13 NH3, followed by C-11 HED PET.
Study NCT03344159 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82
Description: At baseline and 12 weeks, all participants will undergo rest perfusion PET imaging according to standard protocols with either 82-Rb or N-13 NH3, followed by C-11 HED PET.
Study NCT03344159 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac MRI (Gadolinium enhanced)
Description: At baseline and 12 weeks all participants will undergo cMR to assess RV function and structure. We will acquire precontrast T2 and native T1 maps, and post gadolinium T1 maps.
Study NCT01852162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Dabigatran 150mg
Study NCT01852162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study NCT03344159 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac MRI (Gadolinium enhanced)
Description: At baseline and 12 weeks all participants will undergo cMR to assess RV function and structure. We will acquire precontrast T2 and native T1 maps, and post gadolinium T1 maps.
Study NCT00979173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC480
Description: Subjects will be initiated on AC480 300mg orally BID for 14 (+/-2 days) before surgery. After surgery, subjects will continue to be dosed with AC480 until either disease progression or intolerance, and will be evaluated every other cycle (i.e., every 4 weeks).
Study NCT02955277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TECH: Tablet Enhancement of Cognition and Health protocol
Description: Cognitive training using touchscreen tablets (TECH protocol)
Study NCT02955277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care or active standard care
Description: standard occupational therapy or 6-weekly group sessions playing board games and puzzles.
Study NCT04212169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3506
Description: multiple doses
Study NCT04212169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: multiple doses
Study NCT01603940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benazepril
Description: Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.
Study NCT01603940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.
Study NCT02748564 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV
Study NCT04559906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spray and Stretch technique (Ethyl chloride)
Description: Group A receive spray and stretch technique (Ethyl chloride) with conventional treatment.~The upper trapezius muscle stretches on the basis of the Technique originally described by Simons. The subject is seated in a relaxed position on their homolateral hand for anchoring the distal end of the studied muscle. Initially, 3 to 5 parallel sweeps of ethyl chloride spray is applied covering the Upper trapezius muscle. Then, the muscle are positioned in a maximal but tolerable stretch and lengthened until the Physical Therapist felt the muscle tension barrier. This procedure repeated 2 or 3 times.
Study NCT04559906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sustain pressure release
Description: Group B receive sustain pressure release with conventional treatment. Progressive pressure release are considered in two stages. The initial step is to recognize and find the trigger in upper fiber of trapezius, utilizing trigger point palpation. Trigger point felt as firm and restricted hyperirritable knots with in gut of the muscle.~The second step is to applying pressure release ranging from eight to twelve second for each pressure, then it increases gradually for maximum of twenty seconds. The total duration of pressure is five minutes or more until the discharge is felt by the fingers.
Study NCT02748564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01420640 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lower frequency, shorter period of Tai Chi
Description: 12 weeks of supervised Tai Chi classes, 1x/week
Study NCT01420640 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Higher frequency, shorter period of Tai Chi
Description: 12 weeks of supervised Tai Chi classes, 2x/week
Study NCT02748564 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03761914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab is administered at a dose of 200 mg intravenously every 3 weeks on Day 1 of each cycle (3-week cycles) starting on Study Week 6 and continuing for up to 2 years thereafter (Study Week 108). Pembrolizumab is to be administered no earlier than 30 minutes after the administration of GPS on Day 1 of each cycle.
Study NCT01420640 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shorter frequency, longer period of Tai Chi
Description: 24 weeks of supervised Tai Chi classes, 1x/week
Study NCT01420640 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Higher frequency, longer period of Tai Chi
Description: 24 weeks of supervised Tai Chi classes, 2x/week